N6-methyladenosine modification: Regulatory mechanisms and therapeutic potential in sepsis

Biomed Pharmacother. 2023 Dec:168:115719. doi: 10.1016/j.biopha.2023.115719. Epub 2023 Oct 14.

Abstract

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection and is characterized by multiple biological and clinical features. N6-methyladenosine (m6A) modification is the most common type of RNA modifications in eukaryotes and plays an important regulatory role in various biological processes. Recently, m6A modification has been found to be involved in the regulation of immune responses in sepsis. In addition, several studies have shown that m6A modification is involved in sepsis-induced multiple organ dysfunctions, including cardiovascular dysfunction, acute lung injury (ALI), acute kidney injury (AKI) and etc. Considering the complex pathogenesis of sepsis and the lack of specific therapeutic drugs, m6A modification may be the important bond in the pathophysiological process of sepsis and even therapeutic targets. This review systematically highlights the recent advances regarding the roles of m6A modification in sepsis and sheds light on their use as treatment targets for sepsis.

Keywords: Immune response; M(6)A; Multiple organ dysfunction; Post-transcriptional regulation; Sepsis.

Publication types

  • Review

MeSH terms

  • Acute Kidney Injury* / drug therapy
  • Acute Lung Injury* / complications
  • Acute Lung Injury* / drug therapy
  • Humans
  • Sepsis* / genetics

Substances

  • N-methyladenosine